Convulsant bicuculline modifies CNS muscarinic receptor affinity

Area of Science:

• Neuroscience
• Pharmacology
• Epilepsy Research

Background:

• Previous studies linked GABAergic system inhibition (e.g., 3-mercaptopropionic acid) to muscarinic receptor binding changes.
• The cholinergic system is known to influence neuronal excitability and is implicated in experimental epilepsy models.

Purpose of the Study:

• To investigate the relationship between GABAergic and cholinergic systems in seizure activity.
• To analyze muscarinic receptor binding alterations induced by bicuculline (BIC), a GABA-A antagonist, in the rat central nervous system.

Main Methods:

• Rats were administered intraperitoneal injections of bicuculline (BIC) at subconvulsant (1.0 mg/kg) and convulsant (7.5 mg/kg) doses.
• Muscarinic antagonist [3H]-quinuclidinyl benzilate ([3H]-QNB) binding to rat central nervous system membranes was analyzed.
• Changes in binding affinity (Kd) and receptor number were assessed in various brain regions.

Main Results:

• Subconvulsant BIC altered [3H]-QNB binding in the cerebellum (+40%) and hippocampus (-10%).
• Convulsant BIC (inducing seizures) increased binding in cerebellar (+36%) and striatal (+15%) membranes, while decreasing it in the hippocampus (-12%).
• BIC administration modified the dissociation constant (Kd) in a dose- and brain region-dependent manner, without altering receptor site number.

Conclusions:

• Muscarinic receptors exhibit differential susceptibility to BIC across central nervous system areas.
• Observed binding modifications by subconvulsant BIC suggest changes are independent of the seizure process itself.
• Findings underscore the significant role of muscarinic receptors in experimental epilepsy and illustrate neuronal plasticity.